STAT
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
Meghana Keshavan
Rights: fair use excerpt

Reporting by Meghana KeshavanSource: STAT NewsPhoto: Anthony Devlin/Getty Images for AstraZenecaUpdated October 6, 2026
---
Meghana Keshavan · STAT News · Photo: Anthony Devlin/Getty Images for AstraZeneca
Source & Credit
Reporting and photography credited as noted above. Originally published by STAT News.
Members only
Checking your membership…